Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.
Viola D, Valerio L, Molinaro E, Agate L, Bottici V, Biagini A, Lorusso L, Cappagli V, Pieruzzi L, Giani C, Sabini E, Passannati P, Puleo L, Matrone A, Pontillo-Contillo B, Battaglia V, Mazzeo S, Vitti P, Elisei R. Viola D, et al. Among authors: matrone a. Endocr Relat Cancer. 2016 Apr;23(4):R185-205. doi: 10.1530/ERC-15-0555. Endocr Relat Cancer. 2016. PMID: 27207700 Review.
Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
Romei C, Tacito A, Molinaro E, Agate L, Bottici V, Viola D, Matrone A, Biagini A, Casella F, Ciampi R, Materazzi G, Miccoli P, Torregrossa L, Ugolini C, Basolo F, Vitti P, Elisei R. Romei C, et al. Among authors: matrone a. Clin Endocrinol (Oxf). 2015 Jun;82(6):892-9. doi: 10.1111/cen.12686. Epub 2014 Dec 29. Clin Endocrinol (Oxf). 2015. PMID: 25440022
New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations.
Romei C, Casella F, Tacito A, Bottici V, Valerio L, Viola D, Cappagli V, Matrone A, Ciampi R, Piaggi P, Ugolini C, Torregrossa L, Basolo F, Materazzi G, Vitti P, Elisei R. Romei C, et al. Among authors: matrone a. J Med Genet. 2016 Nov;53(11):729-734. doi: 10.1136/jmedgenet-2016-103833. Epub 2016 Jul 28. J Med Genet. 2016. PMID: 27468888
Targeted Therapy in Thyroid Cancer: State of the Art.
Valerio L, Pieruzzi L, Giani C, Agate L, Bottici V, Lorusso L, Cappagli V, Puleo L, Matrone A, Viola D, Romei C, Ciampi R, Molinaro E, Elisei R. Valerio L, et al. Among authors: matrone a. Clin Oncol (R Coll Radiol). 2017 May;29(5):316-324. doi: 10.1016/j.clon.2017.02.009. Epub 2017 Mar 17. Clin Oncol (R Coll Radiol). 2017. PMID: 28318881 Review.
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life.
Matrone A, Valerio L, Pieruzzi L, Giani C, Cappagli V, Lorusso L, Agate L, Puleo L, Viola D, Bottici V, Del Re M, Molinaro E, Danesi R, Elisei R. Matrone A, et al. Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):319-334. doi: 10.1016/j.beem.2017.06.001. Epub 2017 Jun 15. Best Pract Res Clin Endocrinol Metab. 2017. PMID: 28911728 Review.
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience.
Romei C, Tacito A, Molinaro E, Piaggi P, Cappagli V, Pieruzzi L, Matrone A, Viola D, Agate L, Torregrossa L, Ugolini C, Basolo F, De Napoli L, Curcio M, Ciampi R, Materazzi G, Vitti P, Elisei R. Romei C, et al. Among authors: matrone a. Oncol Lett. 2018 Jun;15(6):9174-9182. doi: 10.3892/ol.2018.8470. Epub 2018 Apr 12. Oncol Lett. 2018. PMID: 29805648 Free PMC article.
83 results